All In Biotech

Drug Trial Radar · NCT06930612

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-1)

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Jun 12, 2025

Primary completion

Apr 20, 2026

Study completion Jul 10, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immunogenicity of CM512 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).

Conditions

  • Chronic Rhinosinusitis With Nasal Polyposis

Interventions

  • CM512Biological

    Administered subcutaneous injection

  • PlaceboDrug

    Administered subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nasal Polyps Score (NPS)Time frame: at week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tong-Ren hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.